Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Adult patients with a histologically or cytologically documented metastatic NSCLC, with
tumors that lack activating EGFR mutations and ALK fusions, are eligible for enrollment.
Patients will be randomized in a 1:1:1 ratio to receive treatment with durvalumab +
tremelimumab combination therapy + SoC chemotherapy, durvalumab monotherapy + SoC
chemotherapy, or SoC chemotherapy alone. Tumor evaluation scans will be performed until
objective disease progression as efficacy assessment. All patients will be followed for
survival until the end of the study. An independent data monitoring committee (IDMC) composed
of independent experts will be convened to confirm the safety and tolerability of the
proposed dose and schedule.

Inclusion Criteria:

For inclusion in the study, patients should fulfill the following criteria:

1. Aged at least 18 years.

2. Histologically or cytologically documented Stage IV NSCLC.

3. Confirmed tumor PD-L1 status prior to randomization.

4. Patients must have tumors that lack activating EGFR mutations and ALK fusions.

5. No prior chemotherapy or any other systemic therapy for metastatic NSCLC.

6. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1.

7. No prior exposure to immunemediated therapy, excluding therapeutic anticancer
vaccines.

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are
fulfilled:

1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant.

2. Active or prior documented autoimmune or inflammatory disorders.

3. Brain metastases or spinal cord compression unless the patient's condition is stable
and off steroids.

4. Active infection including tuberculosis, hepatitis B, hepatitis C, or human
immunodeficiency virus.